Seegene Introduces Allplex(TM) Assays Based on MuDT(TM) Next-Generation qPCR Technology - Seite 2

• Allplex™ Respiratory Full Panel(26 targets)
  
  1. Flu/RSV screening and Flu Typing Panel: Influenza A virus, Influenza B virus, RSV type A and B, Influenza A virus subtypes(H1, H3, and H1pdm09)
  2. Virus Screening Panel A: Adenovirus, Enterovirus, Parainfluenza virus(1, 2, 3, and 4)
  3. Virus Screening Panel B: Metapneumovirus, Rhinovirus, Bocavirus, Coronavirus (229E, NL63, and OC43)
  4. Bacteria Screening Panel: M.pneumonia, C.pneumonia, L.pneumophila, B.pertussis, B. parapertussis, S. pneumonia, H. influenza
  
  
• Allplex™ Gastrointestinal Infection Full Panel(26 targets)
  
  1. Virus Screening Panel: Norovirus GI, Norovirus GII, Rotavirus A, Astrovirus, Adenovirus 40/41, Sapovirus
  2. Bacteria Screening Panel A: Campylobacter spp.(C. coli and C. jejuni), Salmonella, Vibrio spp.(V. cholera, V. vulnificus, and V. parahaemolyticus), Y.enterocolitica, C. difficile toxin B, C. difficile tcdCΔ117, Aeromonas spp. (A. hydrophila, A. veronii, and A. caviae)
  3. Bacteria Screening Panel B: E. coli O157, stx1/2, ETEC, EAEC, EPEC, EIEC/Shigella spp.(S. dysenteriae, S. sonnei, S. flexneri, and S. boydii), P.shigelloides
  4. Parasite Screening Panel: E. histolytica, Cryptosporidium spp.(C. parvum and C. hominis), G. lamblia, D. fragilis, C. cayetanensis, and B. hominis
  
  
• Allplex™ Sexually Transmitted Infection Full Panel(27 targets)
  
  1. Essential Screening Panel: C. trachomatis, N.gonorrhoeae, M. genitalium, T. vaginalis, M. hominis, U. urealyticum, U. parvum
  2. Genital Ulcer Screening Panel: HSV 1/2, H. ducreyi, T. pallidum, LGV, CMV
  3. Candidiasis Screening Panel: C. albicans, C. glabrata, C. tropicalis, C. krusei, C. parasilosis, C. dubliniensis, C. lusitaniae
  4. Bacterial Vaginosis Screening Panel: Lactobacillus spp., G. vaginalis, A. vaginae, Megasphaera type 1, BVAB 2, B. fragilis, Mobiluncus spp.
  
  

Seegene is committed to the ongoing development of assays to expand the Allplex™ infectious disease portfolio and aims to submit for CE Mark on the first three assays in 2015. Future menu items will be announced at a later date.

About Seegene
Seegene is the world's leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegene's innovative proprietary technologies, including DPO™, TOCE™, mTOCE™ and MuDT™, can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene endlessly strives toward the new possibility of a world free of disease.

For more information, please visit www.seegene.com or call [phone].

Constantine Theodoropulos
Base Pair Group
617-816-4637